Citations (25)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Victoria Linares, Virginia Alonso & José L Domingo. (2011) Oxidative stress as a mechanism underlying sulfasalazine-induced toxicity. Expert Opinion on Drug Safety 10:2, pages 253-263.
Read now
Read now
Articles from other publishers (24)
Karen van Hoeve & Ilse Hoffman. (2022) Renal manifestations in inflammatory bowel disease: a systematic review. Journal of Gastroenterology 57:9, pages 619-629.
Crossref
Crossref
Lucie Weislinger, Lucas Guillo, Ferdinando D’Amico, Silvio Danese, Hamza Achit, Carole Ayav, Francis Guillemin, Laurent Peyrin-Biroulet & Luc Frimat. (2020) Knowledge of 5-aminosalicylic acid nephrotoxicity and adherence to kidney function monitoring of patients with inflammatory bowel disease. European Journal of Gastroenterology & Hepatology 33:9, pages 1148-1152.
Crossref
Crossref
Lucas Guillo, Ferdinando D'Amico, Hamza Achit, Carole Ayav, Francis Guillemin, Silvio Danese, Luc Frimat & Laurent Peyrin-Biroulet. (2021) Kidney function monitoring to prevent 5-aminosalicylic acid nephrotoxicity: What the gastroenterologist should know. Digestive and Liver Disease 53:6, pages 691-696.
Crossref
Crossref
Seymour Katz & Yingheng Liu. 2021. Geriatric Gastroenterology. Geriatric Gastroenterology
1675
1690
.
Avinash Adiga & David S. Goldfarb. (2020) The Association of Mesalamine With Kidney Disease. Advances in Chronic Kidney Disease 27:1, pages 72-76.
Crossref
Crossref
Seymour Katz & Yingheng Liu. 2020. Geriatric Gastroenterology. Geriatric Gastroenterology
1
16
.
Sheshank Sethi, Rajneet Kaur Khurana, Sunil Kamboj, Radhika Sharma, Akashdeep Singh & Vikas Rana. (2017) Investigating the potential of Tamarindus indica pectin–chitosan conjugate for reducing recovery period in TNBS induced colitis. International Journal of Biological Macromolecules 98, pages 739-747.
Crossref
Crossref
Christina Y. Ha & Seymour Katz. (2013) Clinical implications of ageing for the management of IBD. Nature Reviews Gastroenterology & Hepatology 11:2, pages 128-138.
Crossref
Crossref
Caroline Kerner, James D. Lewis & Mark T. Osterman. 2014. Medical Therapy of Ulcerative Colitis. Medical Therapy of Ulcerative Colitis
297
311
.
Kuldeep Singh, Rajat Suri, A.K. Tiwary & Vikas Rana. (2013) Exploiting the synergistic effect of chitosan–EDTA conjugate with MSA for the early recovery from colitis. International Journal of Biological Macromolecules 54, pages 186-196.
Crossref
Crossref
Javier P. Gisbert, Marta Luna, Yago González-Lama, Inés D. Pousa, Marta Velasco, Ricardo Moreno-Otero & José Maté. (2008) Effect of 5-aminosalicylates on renal function in patients with inflammatory bowel disease: 4-year follow-up study. Gastroenterología y Hepatología 31:8, pages 477-484.
Crossref
Crossref
Javier P. Gisbert, Yago González-Lama & José Maté. (2007) 5-Aminosalicylates and renal function in inflammatory bowel disease. Inflammatory Bowel Diseases 13:5, pages 629-638.
Crossref
Crossref
Peggy Gandia, Isabelle Idier & Georges Houin. (2007) Is Once-Daily Mesalazine Equivalent to the Currently Used Twice-Daily Regimen? A Study Performed in 30 Healthy Volunteers. The Journal of Clinical Pharmacology 47:3, pages 334-342.
Crossref
Crossref
Francesco Di Mario, Giuseppe Comparato, Libera Fanigliulo, Giovanni Aragona, Lucas G. Cavallaro, Giulia M. Cavestro & Angelo Franzé. (2006) Use of Mesalazine in Diverticular Disease. Journal of Clinical Gastroenterology 40:Supplement 3, pages S155-S159.
Crossref
Crossref
D. J. de Jong, J. Tielen, C. M. Habraken, J. F. M. Wetzels & A. H. J Naber. (2005) 5-Aminosalicylates and Effects on Renal Function in Patients with Crohnʼs Disease. Inflammatory Bowel Diseases 11:11, pages 972-976.
Crossref
Crossref
W. J. Sandborn & S. B. Hanauer. (2003) The pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Alimentary Pharmacology & Therapeutics 17:1, pages 29-42.
Crossref
Crossref
E L BerrymanA C Zerouala, C Meschter & J Spenard. (2016) Intrarectal administration of 5-aminosalicylic acid to rabbits and dogs. Human & Experimental Toxicology 21:3, pages 159-163.
Crossref
Crossref
K. R. Herrlinger, M. K. Noftz, K. Fellermann, K. Schmidt, J. Steinhoff & E. F. Stange. (2008) Minimal renal dysfunction in inflammatory bowel disease is related to disease activity but not to 5‐ASA use. Alimentary Pharmacology & Therapeutics 15:3, pages 363-369.
Crossref
Crossref
N. Mahmud, D. G. Weir & D. Kelleher. (1999) Systemic levels of free 5-aminosalicylic acid depend on the nature of the 5-aminosalicyclic acid derivative and not on disease activity or extent in patients with inflammatory bowel disease. Irish Journal of Medical Science 168:4, pages 228-232.
Crossref
Crossref
Peter H. Bach & Nguyen Thi Kim Thanh. (2016) Renal Papillary Necrosis—40 Years On. Toxicologic Pathology 26:1, pages 73-91.
Crossref
Crossref
Jill W. Verlander. (2016) Normal Ultrastructure of the Kidney and Lower Urinary Tract. Toxicologic Pathology 26:1, pages 1-17.
Crossref
Crossref
E. ELTON & S. B. HANAUER. (2007) Review article: The medical management of Crohn's disease. Alimentary Pharmacology & Therapeutics 10:1, pages 1-22.
Crossref
Crossref
Stephen B. Hanauer & Filip Baert. (1994) Medical therapy of inflammatory bowel disease. Medical Clinics of North America 78:6, pages 1413-1426.
Crossref
Crossref
S A Riley, D R Lloyd & V Mani. (1992) Tests of renal function in patients with quiescent colitis: effects of drug treatment.. Gut 33:10, pages 1348-1352.
Crossref
Crossref